• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    12/5/23 12:31:07 PM ET
    $BCLI
    $CERE
    $GRI
    $IBIO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCLI alert in real time by email

    Gainers

    • PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of their outstanding shares is at $31.1 million.
    • Travere Therapeutics (NASDAQ:TVTX) stock moved upwards by 20.66% to $7.59. The market value of their outstanding shares is at $570.3 million.
    • MSP Recovery (NASDAQ:LIFW) stock rose 18.99% to $4.0. The market value of their outstanding shares is at $57.2 million.
    • Xenetic Biosciences (NASDAQ:XBIO) stock rose 17.84% to $4.16. The company's market cap stands at $6.4 million.
    • Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 16.28% to $36.98. The company's market cap stands at $6.6 billion.
    • Kala Bio (NASDAQ:KALA) shares increased by 15.92% to $7.52. The market value of their outstanding shares is at $20.2 million.

    Losers

    • Replimune Group (NASDAQ:REPL) shares decreased by 44.5% to $6.83 during Tuesday's regular session. The company's market cap stands at $403.5 million.
    • iBio (AMEX:IBIO) stock declined by 43.66% to $1.52. The market value of their outstanding shares is at $2.1 million.
    • Seelos Therapeutics (NASDAQ:SEEL) stock decreased by 25.26% to $1.47. The market value of their outstanding shares is at $10.7 million.
    • Mainz Biomed (NASDAQ:MYNZ) stock fell 25.16% to $1.19. The market value of their outstanding shares is at $24.2 million.
    • GRI Bio (NASDAQ:GRI) stock fell 23.35% to $0.57. The company's market cap stands at $1.8 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock declined by 16.45% to $0.33. The market value of their outstanding shares is at $16.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BCLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCLI
    $CERE
    $GRI
    $IBIO

    CompanyDatePrice TargetRatingAnalyst
    Replimune Group Inc.
    $REPL
    11/3/2025$11.00Underperform → Market Perform
    BMO Capital Markets
    Travere Therapeutics Inc.
    $TVTX
    10/31/2025$34.00 → $48.00Buy
    Citigroup
    Replimune Group Inc.
    $REPL
    10/27/2025$12.00Neutral → Buy
    H.C. Wainwright
    iBio Inc.
    $IBIO
    10/21/2025$5.00Outperform
    Oppenheimer
    Replimune Group Inc.
    $REPL
    10/20/2025$13.00Neutral → Overweight
    Piper Sandler
    Replimune Group Inc.
    $REPL
    10/20/2025Underweight → Neutral
    Analyst
    Replimune Group Inc.
    $REPL
    10/20/2025$13.00Market Perform → Outperform
    Leerink Partners
    Replimune Group Inc.
    $REPL
    10/20/2025$18.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $BCLI
    $CERE
    $GRI
    $IBIO
    SEC Filings

    View All

    SEC Form D filed by KALA BIO Inc.

    D - KALA BIO, Inc. (0001479419) (Filer)

    3/17/26 4:59:15 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/17/26 4:21:36 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Travere Therapeutics Inc.

    144 - Travere Therapeutics, Inc. (0001438533) (Subject)

    3/16/26 4:20:20 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CERE
    $GRI
    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

    AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE:TRIP) (FSE: 4YX) (OTCQB:TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ:KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Fil

    3/18/26 9:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

    DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. Leading the narrative is KALA BIO (NASDAQ:KALA), which announced it expects to deploy its first commercial AI agent within approximately two weeks as part of the rebranded Researgency.ai platform. The company is attempting to reposi

    3/11/26 10:00:26 AM ET
    $CYN
    $DOMO
    $KALA
    EDP Services
    Technology
    Computer Software: Prepackaged Software
    Biotechnology: Pharmaceutical Preparations

    $BCLI
    $CERE
    $GRI
    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Reed Elizabeth E

    4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

    3/18/26 4:05:31 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lazar David E.

    4 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    3/3/26 10:13:06 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)

    3 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    3/3/26 10:10:31 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CERE
    $GRI
    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BCLI
    $CERE
    $GRI
    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Replimune upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Replimune from Underperform to Market Perform and set a new price target of $11.00

    11/3/25 9:08:28 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup reiterated coverage on Travere Therapeutics with a new price target

    Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $48.00 from $34.00 previously

    10/31/25 10:57:06 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Replimune upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Replimune from Neutral to Buy and set a new price target of $12.00

    10/27/25 8:31:26 AM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Large owner Donahue Kevin Michael bought $1,034,350 worth of shares (685,000 units at $1.51) (SEC Form 4)

    4/A - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/20/26 10:29:36 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Donahue Kevin Michael bought $258,827,700,000 worth of shares (643,850 units at $402,000.00) (SEC Form 4)

    4 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/16/26 3:42:37 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:37 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CERE
    $GRI
    $IBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

    BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection

    9/30/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CERE
    $GRI
    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCLI
    $CERE
    $GRI
    $IBIO
    Financials

    Live finance-specific insights

    View All

    iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

    SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio's strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and will include a presentation from Martin Brenner, DVM, Ph.D., iBio's Chief Executive Officer and Chief Scientific Officer, and Cory Schwartz, Ph.D., the Company's Director of Research and Early Development. iBio is engineering a selective bispecific antibo

    3/16/26 4:30:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

    2/19/26 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi

    2/12/26 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care